Researchers believe they have solved vaccine blood-clot puzzle

‘All mRNA-based vaccines should represent safe products,’ paper says

Samuel Osborne
Thursday 27 May 2021 10:20
Comments
<p>A vial of the AstraZeneca Covid-19 jab</p>

A vial of the AstraZeneca Covid-19 jab

Scientists in Germany believe they have found the cause of the rare blood clots linked to the Oxford/AstraZeneca and Johnson & Johnson coronavirus vaccines.

If borne out, the findings could lead to the jabs being altered in order to prevent the reaction.

The researchers, in a study which is yet to be reviewed by experts, said Covid-19 vaccines that employ adenovirus vectors - cold viruses used to deliver vaccine material - send some of their payload into the nucleus of cells, where some of the instructions for making coronavirus proteins could be misread, with the resulting proteins potentially triggering blood clot disorders in a small number of recipients.

Scientists and drug regulators have been searching for an explanation for the rare but potentially fatal clots accompanied by low blood platelet counts, which have led some countries to halt or limit the use of the AstraZeneca and J&J vaccines.

Johnson & Johnson, in a statement said: "We are supporting continued research and analysis of this rare event as we work with medical experts and global health authorities. We look forward to reviewing and sharing data as it becomes available." AstraZeneca declined to comment.

Researchers at the Goethe-University of Frankfurt and other sites explained that vaccines using a different technology known as messenger RNA (mRNA), such as those developed by BioNTech with Pfizer and Moderna, deliver the genetic material of the coronavirus spike protein only to fluid found inside cells, not to the nucleus of the cells.

“All mRNA-based vaccines should represent safe products,” the paper said.

It suggests vaccine makers using adenovirus vectors could modify the sequence of the spike protein “to avoid unintended splice reactions and to increase the safety of these pharmaceutical products.”

It comes as doctors in the UK have been urged to look for signs of stroke in people receiving the Oxford/AstraZeneca vaccine after three young patients were admitted to hospital and one died.

Experts, including from the National Hospital for Neurology and Neurosurgery at University College London (UCL) Hospitals NHS Foundation Trust, told how two women in their 30s and a man in his 40s suffered clots in their large arteries, leading to ischaemic stroke, though they stressed the chances were small.

The team said the NHS must look out for patients with ischaemic stroke (where blood clots block arteries) within about one month of vaccination, saying they should be "urgently evaluated" for a very rare syndrome called vaccine-induced thrombosis and thrombocytopenia.

This condition needs to be rapidly diagnosed and managed by a team with a range of expertise, who have quick access to a range of drugs, they said. The experts stressed that the cases of stroke are very rare and that stroke is more common in people who catch Covid-19.

There have been 309 cases of major thrombosis with low platelet count suggesting VITT from more than 30 million doses of the AstraZeneca vaccine administered, they said.

The number of people who experience blood clots from VITT after a Covid-19 vaccine is therefore extremely low at about one per 100,000 doses.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in